AR065844A1 - Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia. - Google Patents
Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia.Info
- Publication number
- AR065844A1 AR065844A1 ARP080101208A ARP080101208A AR065844A1 AR 065844 A1 AR065844 A1 AR 065844A1 AR P080101208 A ARP080101208 A AR P080101208A AR P080101208 A ARP080101208 A AR P080101208A AR 065844 A1 AR065844 A1 AR 065844A1
- Authority
- AR
- Argentina
- Prior art keywords
- diseases
- independently selected
- atom
- heteroaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto caracterizado por la formula (1) o una sal, solvato o hidrato farmacologicamente aceptable de dicho compuesto, donde A es un heteroarilo de 6 miembros que tiene de 1 a 3 heteroátomos cada uno independientemente seleccionado de N o O,donde dicho heteroarilo de 6 miembros está sustituido con entre 2 y 4 sustituyentes cada uno independientemente seleccionado de un átomo de halogeno, un átomo de oxígeno, hidroxi, ciano, amino, nitro, mercapto, alquilo, alquenilo, alquinilo,heteroalquilo, cicloalquilo, heterocicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; R5 es un átomo de halogeno, hidroxi, ciano, nitro, mercapto, alquilo, alquenilo, alquinilo oheteroalquilo; R6 es alquilo opcionalmente sustituido; alquenilo opcionalmente sustituido; heterocicloalquilo de 5 miembros que tiene de 1 a 3 heteroátomos cada uno independientemente seleccionado de N, O o S, o cicloalquilo, donde dichoheterocicloalquilo de 5 miembros o cicloalquilo está sustituido con entre 0 y 3 sustituyentes cada uno independientemente seleccionado de un átomo de halogeno, un átomo de oxígeno, hidroxi, ciano, amino, nitro, mercapto, alquilo, alquenilo,alquinilo, heteroalquilo, cicloalquilo, heterocicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; heteroarilo de 5 miembros que tiene de 1 a 4 heteroátomos cada uno independientementeseleccionado de N, O o S, donde dicho heteroarilo de 5 miembros está sustituido con entre 0 y 3 sustituyentes cada uno independientemente seleccionado de un átomo de halogeno, un átomo de oxígeno, hidroxi, ciano, amino, nitro, mercapto, alquilo,alquenilo, alquinilo, heteroalquilo, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; o -S-R10; R10 es heterocicloalquilo de 5 miembros que tiene de 1 a 3 heteroátomos cada uno independientemente seleccionado de N, O o S, ocicloalquilo, donde dicho heterocicloalquilo 5 miembros o cicloalquilo está sustituido con entre 0 y 4 sustituyentes cada uno independientemente seleccionado de un átomo de halogeno, un átomo de oxígeno, hidroxi, ciano, amino, nitro, mercapto,alquilo, alquenilo, alquinilo, heteroalquilo, cicloalquilo, heterocicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; o heteroarilo de 5 miembros que tiene de 1 a 4 heteroátomos cada unoindependientemente seleccionado de N, O o S, donde dicho heteroarilo de 5 miembros está sustituido con entre 0 y 4 sustituyentes cada uno independientemente seleccionado de un átomo de halogeno, un átomo de oxígeno, hidroxi, ciano, amino, nitro,mercapto, alquilo, alquenilo, alquinilo, heteroalquilo, cicloalquilo, heterocicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; R7 es un átomo de hidrogeno, un átomo de halogeno, hidroxi,ciano, amino, nitro, alquilo o heteroalquilo; R8 es un átomo de hidrogeno o un átomo de halogeno; y R17 es un átomo de hidrogeno o un átomo de halogeno. Uso de los mismos en trastornos dérmicos; enfermedades oculares; enfermedades del oído;enfermedades de la boca, la garganta y las vías respiratorias; enfermedades gastrointestinales; enfermedades del hígado, la vesícula biliar y el páncreas; enfermedades del tracto urinario y los rinones; enfermedades de los organos genitalesmasculinos y los organos genitales femeninos; enfermedades del sistema hormonal; enfermedades metabolicas; enfermedades cardiovasculares; enfermedades de la sangre; enfermedades linfáticas; trastornos del sistema nervioso central; trastornoscerebrales; enfermedades del sistema musculoesquelético; trastornos alérgicos; dolor; enfermedades infecciosas; trastornos inflamatorios; heridas; trastornos inmunologicos; cáncer; enfermedades hereditarias; o edema,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07006089 | 2007-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065844A1 true AR065844A1 (es) | 2009-07-08 |
Family
ID=39473755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101208A AR065844A1 (es) | 2007-03-23 | 2008-03-25 | Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia. |
Country Status (19)
Country | Link |
---|---|
US (1) | US8410134B2 (es) |
EP (2) | EP2305668A1 (es) |
KR (1) | KR20090125779A (es) |
CN (1) | CN101679375A (es) |
AR (1) | AR065844A1 (es) |
AT (1) | ATE485289T1 (es) |
AU (1) | AU2008232021B2 (es) |
BR (1) | BRPI0809231A2 (es) |
CA (1) | CA2681206C (es) |
DE (1) | DE602008003116D1 (es) |
DK (1) | DK2144897T3 (es) |
ES (1) | ES2356197T3 (es) |
IL (1) | IL200922A0 (es) |
MX (1) | MX2009010246A (es) |
PL (1) | PL2144897T3 (es) |
RU (1) | RU2512541C2 (es) |
TW (1) | TWI407960B (es) |
WO (1) | WO2008116620A1 (es) |
ZA (1) | ZA200906307B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
AR073304A1 (es) * | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
SG11201403645VA (en) | 2011-12-28 | 2014-07-30 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10039846B2 (en) | 2012-09-13 | 2018-08-07 | British Columbia Cancer Agency Branch | Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders |
BR112015022846A2 (pt) * | 2013-03-14 | 2017-11-07 | Shire Human Genetic Therapies | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
CA2902874C (en) * | 2013-03-15 | 2021-04-20 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-benzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA033555B1 (ru) | 2013-03-15 | 2019-10-31 | Global Blood Therapeutics Inc | Фармацевтические композиции для лечения серповидно-клеточного нарушения |
AU2014237340C1 (en) | 2013-03-15 | 2018-11-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
AU2015371822B2 (en) * | 2014-12-24 | 2020-04-09 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
CN106866432A (zh) * | 2017-03-31 | 2017-06-20 | 九江善水科技股份有限公司 | 一种硝基苯酚及其中间体的合成工艺 |
UY37981A (es) * | 2017-11-24 | 2019-06-28 | Pharvaris B V | Novedosos antagonistas del receptor b2 de bradiquinina |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
UY38707A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina |
UY38706A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
DK4203919T3 (da) | 2021-08-05 | 2024-04-29 | Pharvaris Gmbh | Lipidbaseret sammensætning til oral administration af bradykinin-b2-receptorantagonister |
TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽b2受體拮抗劑之固態延長釋放組成物 |
WO2023180577A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Therapeutic uses of bradykinin b2-receptor antagonists |
WO2023180575A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU680870B2 (en) * | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
CN1168667A (zh) | 1994-10-27 | 1997-12-24 | 藤沢药品工业株式会社 | 用作缓激肽拮抗剂的吡啶并嘧啶酮,喹啉和稠合的n-杂环化合物 |
FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
GB9519077D0 (en) * | 1995-09-18 | 1995-11-15 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
AUPN952696A0 (en) * | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
AU4335299A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Bradykinin antagonists |
WO2000023439A1 (en) | 1998-10-21 | 2000-04-27 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
AU2001229580A1 (en) | 2000-01-18 | 2001-08-14 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
WO2003087090A2 (en) | 2002-04-10 | 2003-10-23 | Ortho-Mcneil Pharmaceutical,Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
-
2008
- 2008-03-21 TW TW097110110A patent/TWI407960B/zh not_active IP Right Cessation
- 2008-03-22 EP EP10013778A patent/EP2305668A1/en not_active Withdrawn
- 2008-03-22 EP EP08716679A patent/EP2144897B1/en active Active
- 2008-03-22 CN CN200880016505A patent/CN101679375A/zh active Pending
- 2008-03-22 AU AU2008232021A patent/AU2008232021B2/en not_active Ceased
- 2008-03-22 DK DK08716679.9T patent/DK2144897T3/da active
- 2008-03-22 KR KR1020097019768A patent/KR20090125779A/ko not_active Application Discontinuation
- 2008-03-22 AT AT08716679T patent/ATE485289T1/de active
- 2008-03-22 PL PL08716679T patent/PL2144897T3/pl unknown
- 2008-03-22 RU RU2009139087/04A patent/RU2512541C2/ru not_active IP Right Cessation
- 2008-03-22 BR BRPI0809231-1A patent/BRPI0809231A2/pt not_active IP Right Cessation
- 2008-03-22 DE DE602008003116T patent/DE602008003116D1/de active Active
- 2008-03-22 WO PCT/EP2008/002316 patent/WO2008116620A1/en active Application Filing
- 2008-03-22 US US12/532,703 patent/US8410134B2/en not_active Expired - Fee Related
- 2008-03-22 CA CA2681206A patent/CA2681206C/en not_active Expired - Fee Related
- 2008-03-22 MX MX2009010246A patent/MX2009010246A/es active IP Right Grant
- 2008-03-22 ES ES08716679T patent/ES2356197T3/es active Active
- 2008-03-25 AR ARP080101208A patent/AR065844A1/es not_active Application Discontinuation
-
2009
- 2009-09-10 ZA ZA200906307A patent/ZA200906307B/xx unknown
- 2009-09-14 IL IL200922A patent/IL200922A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200906307B (en) | 2010-04-28 |
EP2144897A1 (en) | 2010-01-20 |
CA2681206A1 (en) | 2008-10-02 |
RU2512541C2 (ru) | 2014-04-10 |
DE602008003116D1 (de) | 2010-12-02 |
AU2008232021B2 (en) | 2012-05-24 |
WO2008116620A1 (en) | 2008-10-02 |
KR20090125779A (ko) | 2009-12-07 |
BRPI0809231A2 (pt) | 2014-09-02 |
AU2008232021A1 (en) | 2008-10-02 |
ES2356197T3 (es) | 2011-04-05 |
ATE485289T1 (de) | 2010-11-15 |
TW200843767A (en) | 2008-11-16 |
IL200922A0 (en) | 2010-05-17 |
US20100234344A1 (en) | 2010-09-16 |
CA2681206C (en) | 2014-04-29 |
EP2144897B1 (en) | 2010-10-20 |
PL2144897T3 (pl) | 2011-04-29 |
DK2144897T3 (da) | 2011-02-07 |
TWI407960B (zh) | 2013-09-11 |
CN101679375A (zh) | 2010-03-24 |
EP2305668A1 (en) | 2011-04-06 |
MX2009010246A (es) | 2009-11-18 |
RU2009139087A (ru) | 2011-04-27 |
US8410134B2 (en) | 2013-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065844A1 (es) | Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia. | |
AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
AR070517A1 (es) | Piperidinas inhibidoras de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
TW200626154A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
AR069207A1 (es) | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 | |
AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
TW200624427A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626153A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
TW200626139A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
TW200626572A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626155A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
MA34604B1 (fr) | Derives de la pyrazine en tant que bloqueurs de l'enac | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
AR076949A1 (es) | Derivados de 1h-imidazo-(4,5-c)-quinolinona | |
AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 | |
BRPI0517425A (pt) | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto | |
ECSP12011695A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |